TWiV 1073: Taming the shrew and barring Epstein-Barr virus

12/24/23 • 98 min

1 Listener

TWiV explains a study showing that ost traits shape virome composition and virus transmission in wild bats, rodents, and shrews, and development of a gB nanoparticle vaccine that elicits a protective neutralizing antibody response against Epstein-Barr virus.

Hosts: Vincent Racaniello, Dickson Despommier, and Kathy Spindler

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

MicrobeTV Discord Server
MicrobeTV store at Cafepress
Become a member of ASV (asv.org)
Research assistant position in Rosenfeld Lab CBER/FDA (pdf)
The New City by Dickson Despommier
Brett Lindenbach passes (Yale Medicine)
Virome of small mammals (Cell)
Epstein-Barr virus nanoparticle vaccine (Cell Host Micr)
Letters read on TWiV 1073
Timestamps by Jolene. Thanks!

Weekly Picks

Dickson – Summary of Global Climate Action at COP 28 and Notable Deaths 2023: Music Kathy – Two APODS Winter solstice, 183 Days in the Sun and the Same color illusion Vincent – The American Academy of Microbiology discusses gain-of-function research of concern (GOFROC) and enhanced potential pandemic pathogens (ePPP)

Listener Picks

Gregory – Climate Change – A revised prediction – Steven Chu John – Detergent packs are kinda wishy-washy (Technology Connections)

Intro music is by Ronald Jenkees

Send your virology questions and comments to [email protected]

Hosts: Vincent Racaniello, Dickson Despommier, and Kathy Spindler

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

MicrobeTV Discord Server
MicrobeTV store at Cafepress
Become a member of ASV (asv.org)
Research assistant position in Rosenfeld Lab CBER/FDA (pdf)
The New City by Dickson Despommier
Brett Lindenbach passes (Yale Medicine)
Virome of small mammals (Cell)
Epstein-Barr virus nanoparticle vaccine (Cell Host Micr)
Letters read on TWiV 1073
Timestamps by Jolene. Thanks!

Weekly Picks

Listener Picks

Gregory – Climate Change – A revised prediction – Steven Chu John – Detergent packs are kinda wishy-washy (Technology Connections)

Intro music is by Ronald Jenkees

Send your virology questions and comments to [email protected]

Previous Episode

TWiV 1072: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses the annual economic burden of respiratory syncytial virus in adults in the US, recombinant or standard-dose influenza vaccine in adults under 65 years of age, maternal vaccine effectiveness against influenza-associated hospitalizations and emergency department visits in iInfants, influenza positive tests reported to CDC by US clinical laboratories, update on COVID-19, risk of severe maternal morbidity associated with SARS-CoV-2 infection during pregnancy, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation, long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study, and risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

RSV economic burden, US (J Inf Dis)
Recombinant or standard dose influenza vaccine (NEJM)
Maternal vaccine effectiveness against influenza in Infants (JAMA Ped)
Weekly influenza surveillance report (MMWR)
COVID data tracker (hospital admissions, national trend)
Risk of severe maternal morbidity associated with SARS-CoV-2 infection (J Inf Dis)
COVID-19 rapid antigen tests with nasal and throat swab specimens (JAMA Net Open)
Optimal timing of nirmatrelvir/ritonavir (Nat Comm)
Long-term outcomes following hospital admission for COVID-19 vs influenza (Lancet)
Contribute to our MicrobeTV fundraiser at PWB
Letters read on TWiV 1072
Dr. Griffin’s COVID treatment summary (pdf)
Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

Next Episode

TWiV 1074: Clinical update with Dr. Daniel Griffin

1 Recommendations

In his weekly clinical update, Dr. Griffin discusses the outcomes of SARS-CoV-2, influenza and respiratory syncytial virus infection in pediatric communities under the age of 18 years, the treatment of infants with the human monoclonal anti-respiratory syncytial virus antibody to prevent hospitalizations, most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, how the SARS-CoV-2/COVID-19 pandemic affected school attendance and child healthcare, how exposure length influenced transmission of SARS-CoV-2, how the durability of the anti-SARS-CoV-2 antibody response to protect against virus re-infection, if administration of oral antiviral therapy affected viral rebound in either the unvaccinated or vaccinated populations, as well as a reminder of the ineffectiveness of antibiotics for treating COVID-19 and the effect of vaccination on post-COVID conditions in children between 5-17 years old.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode